1 / 12

Pharmaceuticals Inc.

Pharmaceuticals Inc. Nasdaq - QCOR. Company Profile. Healthcare Biotechnology Market Cap - 3.3 Billion Aggressive Growth Stock Anaheim, California 557 Employees. QCOR.

clint
Télécharger la présentation

Pharmaceuticals Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceuticals Inc. Nasdaq - QCOR

  2. Company Profile • Healthcare • Biotechnology • Market Cap - 3.3 Billion • Aggressive Growth Stock • Anaheim, California • 557 Employees

  3. QCOR • What Does This Company Do? Questcor Pharmaceuticals Inc is a biopharmaceutical company, that provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. • Acthar Gel- treatment of acute exacerbations of multiple sclerosis • Acthar - $621 Million in sales – approved for 19 conditions • Acthar Phase II trials- Treatment for ALS – FDA request for orphan designation

  4. Competitors • Roche Holding • Novo Nordisk • Gilead Science Inc. • Lundbeck • Novartis • Sanofi

  5. Key Stats (ms)

  6. Groupthink

  7. Pros • Low debt (10% of Cap’l) • Relatively Low PE (16) and pays dividend (1.70%) (raising quarterly dividend by 20%) • VL projects 11% - 22% return • Has expanding use of Acthar with great success • Mid Cap • Named Forbes Best Small Public Company (5yr est. sales – 51%, est. growth 41%) • MS rated 5.0 – Buy • Yahoo 1.5 – Buy • Motley Fool Quote “Simply put, Questcor looks very cheap”

  8. Cons • Tremendous Growth – 52 weeks - $19.90 – $74.76 • Business appears to be focused on the development of one major drug • Club portfolio contains 3 biotech stocks(?) • Zacks - 3 • VL “some reimbursement concerns”

  9. CLASSIC VL QUOTE “long term investors should consider these shares”

  10. My Recommendation: Buy

More Related